376 results on '"Rustin, Gordon"'
Search Results
2. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial
3. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
4. Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer
5. Evaluating prognostic models for stage I seminoma within the randomised trial of imaging and surveillance in seminoma testis (TRISST).
6. #872 Malignant ovarian germ cell tumours: an international multicentre study to identify new prognostic risk factors
7. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
8. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
9. Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study.
10. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
11. Data from Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents
12. Supplementary Figures 1-2 from Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents
13. Supplementary Methods from Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents
14. Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma in the TRISST trial.
15. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
16. Recurrent Ovarian Cancer: When to Treat and How to Assess
17. Depth of Response to Primary Chemotherapy Predicts Survival in Poor Prognosis Germ-Cell Tumours
18. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
19. A North-West London Experience of the Impact of Treatment Related Toxicity on Clinical Outcomes of Elderly Patients with Germ Cell Tumors
20. The Clinical Development of Tubulin Binding Vascular Disrupting Agents
21. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
22. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
23. Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities
24. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients
25. Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer
26. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
27. Runs of homozygosity and testicular cancer risk
28. Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
29. Recurrent Ovarian Cancer: When and How to Treat
30. Recurrent Ovarian Cancer: When to Treat and How to Assess
31. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations
32. Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours
33. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
34. Clinical Progress in Tumor Vasculature-disrupting Therapies
35. Appendix_rev3_clean – Supplemental material for Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application
36. Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors
37. Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment
38. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide
39. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
40. Can We Now Agree to Use the Same Definition to Measure Response According to CA-125?
41. Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
42. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
43. Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging
44. Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
45. Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials
46. Progress in the Management of Gynecologic Cancer: Consensus Summary Statement
47. Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging
48. Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels
49. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
50. Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.